PTGS2 and neoplasm: Considering that each metabolite has a specific role in moderating tumor cells and neighboring immune cells (15–17, 32–36), it is likely that different profiles of prostaglandins released by tumor cells during genetic or pharmacologic depletion of COX-2 and mPGES-1 may lead to different phenotypes or functional properties of antitumor immune cells.